IDEXX Laboratories (IDXX) investor relations material

Business performance and growth outlook

• Achieved strong Q2 results and raised full-year guidance, reflecting robust momentum and double-digit recurring revenue growth in reference labs and VetLab platforms.

• Reaffirmed long-term targets of 10%+ organic revenue growth and 15%+ EPS growth, supported by innovation and utilization.

• Recurring revenue streams drive high incremental gross margin and enable reinvestment in R&D and commercial expansion.

• Operating margin improvement targeted at 50–100 basis points annually, with over 32% operating margin guided for the year.

• International regions are experiencing strong double-digit growth as customer base broadens and diagnostic utilization expands.

Market trends and sector dynamics

• Veterinary office visits are experiencing modest headwinds, particularly in wellness, but total pet and medicalized pet populations have grown significantly since pre-pandemic.

• Demand for care is resilient across economic cohorts, with aging pets and breed mix changes driving higher care intensity and diagnostic needs.

• Diagnostic inclusion in visits remains low, presenting a significant opportunity for further growth in utilization.

• Structural shift observed toward higher quality and intensity of care per visit, with durable high single-digit utilization metrics.

Innovation and product development

• IDEXX inVue Dx launch has exceeded expectations, with recurring revenue per instrument within the $3,500–$5,500 range and significant headroom for growth as FNA rolls out.

• Innovations like FNA on inVue Dx are doubling diagnostic volumes at 85% lower cost, transforming manual processes and expanding care.

• Platform approach enables rapid onboarding of new diagnostic applications, supporting future consumable revenue growth.

• MultiQ Dx, a new diagnostic platform, will be unveiled at VMX in January, expected to be paradigm-changing and complementary to existing offerings.